Everygene Launches Free Genetic Testing for Cardiomyopathy Patients; Initiative Powered by Broad Clinical Labs and the Laboratory for Molecular Medicine at Mass General Brigham  

CAMBRIDGE, Mass., July 23, 2025 /PRNewswire/ -- Everygene, a precision health company dedicated to expanding access to genetic insights for families affected by inherited disease, today announced the launch of a nationwide, no-cost genetic testing program for individuals with cardiomyopathy. The initiative is conducted in collaboration with Broad Clinical Labs (BCL) and the Laboratory for Molecular Medicine (LMM) at Mass General Brigham, integrating advanced genomic technologies with expert clinical interpretation to improve diagnostic outcomes for patients with suspected genetic cardiomyopathy. 

Cardiomyopathy is a disease of the heart muscle that can lead to heart failure and sudden cardiac death, affecting over one million people in the United States. Despite strong evidence supporting a genetic basis in many cases, fewer than 2% of patients currently receive genetic testing. This gap can result in delayed or missed diagnoses and prevents at-risk family members from receiving appropriate assessment and intervention.  

Through this new program, Everygene aims to eliminate financial and logistical barriers to testing by offering molecular analysis and genetic counseling services at no cost to patients. Molecular testing is provided by Broad Clinical Labs using its high-resolution blended genome-exome product, optimized for detecting rare, clinically relevant variants with enhanced sensitivity. Expert interpretation and clinical reporting are conducted by the Laboratory for Molecular Medicine at Mass General Brigham, leveraging its extensive experience in cardiovascular genetics to assess a curated panel of genes known to be associated with cardiomyopathy. 

"Most people with genetic cardiomyopathy are never tested, despite its potential to prevent serious outcomes," said Jeb Balise, founder and CEO of Everygene. "This nationwide program expands access to advanced testing and expert interpretation at no cost, so more patients can get the answers they need." 

"Our blended genome-exome assay enables us to go beyond traditional panels by capturing a broader range of disease-relevant variation," said Dr. Sean Hofherr, Chief of Clinical Product and Development at Broad Clinical Labs. "We're proud to support this initiative with technology that delivers clinical-grade performance on a scalable platform." 

"Accurate variant classification is essential to making genetics actionable," said Dr. Matt Lebo, Director of the Laboratory for Molecular Medicine at Mass General Brigham. "Our team brings decades of experience interpreting cardiomyopathy genes. It's important that these results are meaningful and accessible to patients and their families." 

The program is open to individuals in the U.S. who have a clinical diagnosis of cardiomyopathy. Optional cascade testing is available for at-risk relatives. All results are delivered with the support of certified genetic counselors to help patients and families understand their findings and appropriate next steps. 

To learn more about eligibility or to enroll, visit www.everygene.com. 

About Everygene 

Everygene is a precision health company on a mission to make life-saving genetic information accessible to everyone. By delivering hospital-grade testing and expert interpretation directly to people's homes, Everygene empowers individuals and families to uncover inherited risks and take proactive steps toward better health. Its cardiomyopathy program, developed in collaboration with Broad Clinical Labs and the Laboratory for Molecular Medicine at Mass General Brigham, is the first in a series of initiatives aimed at expanding access to genetic insights for conditions where early detection can improve outcomes and save lives. Learn more at www.everygene.com. 

About Broad Clinical Labs  

Broad Clinical Laboratories was founded in 2013 as a non-profit subsidiary of Broad Institute of MIT and Harvard to accelerate the world toward a better understanding, diagnosis, and treatment of disease by pursuing projects, developing products, and driving adoption of cutting edge -omics technologies and novel molecular assays. Learn more at www.broadclinicallabs.org. 

For more information, please contact:
[email protected]

SOURCE Broad Clinical Labs; Everygene